What is Atea Pharmaceuticals, Inc.'s earnings per share (EPS)?

Atea Pharmaceuticals, Inc. (AVIR) reported diluted earnings per share of $-1.94 for fiscal year 2025. This represents a 3.0% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

Atea Pharmaceuticals, Inc. Financials

AVIR

Source SEC Filings (10-K/10-Q) Updated Mar 31, 2026 Currency USD FYE December

This page shows Atea Pharmaceuticals, Inc. (AVIR) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 8 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Rhea AI AVIR FY2025 2026-04-22

A cash-funded development model dominates as balance-sheet assets are recycled into liquidity to sustain heavy research spending and operations.

FY2025 operations used $132.0M, but $188.8M came in from investing activity. Because cash still ended higher than the prior year, the liquidity story is not operating improvement; it is turning non-operating assets into cash so the research program can continue without leaning on debt.

R&D stayed high at $148.0M in FY2025, while SG&A fell to $32.9M. That mix says the business is still organized around development rather than commercialization, and the slight improvement in operating loss came more from trimming support costs than from dialing back core research.

Equity dropped from $438.9M to $275.4M in one year even though liabilities remained modest and no long-term debt was reported. The balance sheet is therefore being consumed mainly by recurring losses, making internal cash resources the key operating constraint rather than creditor pressure or debt service.

Financial Health Signals

Financial Profile 33/100

Based on FY2025 annual data, averaged across the last 3 years for performance metrics (most-recent year weighted highest). How this score is calculated →

Health score ≠ stock price. This rates the quality of Atea Pharmaceuticals, Inc.'s business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.

Leverage

Atea Pharmaceuticals, Inc. carries a low D/E ratio of 0.14, meaning only $0.14 of long-term debt for every $1 of shareholders' equity. This conservative leverage earns a score of 99/100, indicating a strong balance sheet with room for future borrowing.

Liquidity

100

With a current ratio of 7.82, Atea Pharmaceuticals, Inc. holds $7.82 in current assets for every $1 of short-term obligations. This comfortable liquidity earns a score of 100/100.

Returns

Atea Pharmaceuticals, Inc. generates a -57.4% ROE, indicating limited profit relative to shareholders' investment. This results in a returns score of 0/100. This is down from -38.3% the prior year.

Piotroski F-Score Weak

2/9

Atea Pharmaceuticals, Inc. passes 2 of 9 financial strength tests. 1 of 4 profitability signals pass, 1 of 3 leverage/liquidity signals pass.

Earnings Quality Low Quality

0.84x

For every $1 of reported earnings, Atea Pharmaceuticals, Inc. generates $0.84 in operating cash flow (-$132.0M OCF vs -$158.0M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue

N/A

EBITDA

-$180.5M

YoY+6.3%

Atea Pharmaceuticals, Inc.'s EBITDA was -$180.5M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 6.3% from the prior year.

Net Income

-$158.0M

YoY+6.0%

Atea Pharmaceuticals, Inc. reported -$158.0M in net income in fiscal year 2025. This represents an increase of 6.0% from the prior year.

EPS (Diluted)

$-1.94

YoY+3.0%

Atea Pharmaceuticals, Inc. earned $-1.94 per diluted share (EPS) in fiscal year 2025. This represents an increase of 3.0% from the prior year.

Cash & Balance Sheet

Free Cash Flow

N/A

Cash & Debt

$95.7M

YoY+47.9%

5Y CAGR-35.4%

Atea Pharmaceuticals, Inc. held $95.7M in cash against $0 in long-term debt as of fiscal year 2025.

Dividends Per Share

N/A

Shares Outstanding

78M

YoY-7.5%

5Y CAGR-1.1%

Atea Pharmaceuticals, Inc. had 78M shares outstanding in fiscal year 2025. This represents a decrease of 7.5% from the prior year.

Margins & Returns

Gross Margin

N/A

Operating Margin

N/A

Net Margin

N/A

Return on Equity

-57.4%

YoY-19.1pp

5Y CAGR-55.4pp

Atea Pharmaceuticals, Inc.'s ROE was -57.4% in fiscal year 2025, measuring profit generated per dollar of shareholder equity. This is down 19.1 percentage points from the prior year.

Capital Allocation

R&D Spending

$148.0M

YoY+2.7%

5Y CAGR+31.2%

Atea Pharmaceuticals, Inc. invested $148.0M in research and development in fiscal year 2025. This represents an increase of 2.7% from the prior year.

Share Buybacks

$25.5M

Atea Pharmaceuticals, Inc. spent $25.5M on share buybacks in fiscal year 2025, returning capital to shareholders by reducing shares outstanding.

Capital Expenditures

N/A

AVIR Income Statement

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Revenue	N/A	N/A	N/A	N/A	$351.4M+622.5%	$48.6M
Cost of Revenue	N/A	N/A	N/A	N/A	N/A	N/A
Gross Profit	N/A	N/A	N/A	N/A	N/A	N/A
R&D Expenses	$148.0M+2.7%	$144.1M+26.1%	$114.2M+39.4%	$81.9M-51.0%	$167.2M+339.7%	$38.0M
SG&A Expenses	$32.9M-32.7%	$48.8M-2.1%	$49.9M+2.5%	$48.7M+6.4%	$45.8M+111.6%	$21.6M
Operating Income	-$180.9M+6.3%	-$192.9M-17.5%	-$164.2M-25.7%	-$130.7M-194.4%	$138.4M+1354.6%	-$11.0M
Interest Expense	N/A	N/A	N/A	N/A	N/A	N/A
Income Tax	-$6.2M-766.2%	$925K-9.1%	$1.0M+128.4%	-$3.6M-120.6%	$17.4M	N/A
Net Income	-$158.0M+6.0%	-$168.0M-23.5%	-$136.0M-17.2%	-$116.0M-195.9%	$121.0M+1205.3%	-$10.9M
EPS (Diluted)	$-1.94+3.0%	$-2.00-22.7%	$-1.63-17.3%	$-1.39-201.5%	$1.37+368.6%	$-0.51

Metric	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24
Revenue	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Cost of Revenue	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Gross Profit	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
R&D Expenses	$41.1M	N/A	$38.3M+18.8%	$32.3M+9.1%	$29.6M	N/A	$26.2M-24.6%	$34.7M
SG&A Expenses	$6.9M	N/A	$7.2M-20.4%	$9.1M-4.1%	$9.5M	N/A	$11.0M-9.6%	$12.2M
Operating Income	-$48.0M	N/A	-$45.6M-10.2%	-$41.3M-5.9%	-$39.0M	N/A	-$37.2M+20.7%	-$46.9M
Interest Expense	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Income Tax	$50K	N/A	$196K-5.3%	$207K+2.0%	$203K	N/A	$226K-7.0%	$243K
Net Income	-$45.4M	N/A	-$42.0M-13.2%	-$37.2M-8.4%	-$34.3M	N/A	-$31.2M+23.1%	-$40.5M
EPS (Diluted)	$-0.57	N/A	$-0.53-20.5%	$-0.44-10.0%	$-0.40	N/A	$-0.37+22.9%	$-0.48

AVIR Balance Sheet

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Total Assets	$315.2M-32.2%	$464.7M-21.9%	$595.0M-10.8%	$666.7M-13.7%	$772.9M-10.5%	$863.6M
Current Assets	$311.0M-32.7%	$462.4M-21.7%	$590.5M-10.7%	$660.9M-14.4%	$772.4M-10.5%	$863.5M
Cash & Equivalents	$95.7M+47.9%	$64.7M-55.0%	$143.8M-23.7%	$188.5M-75.3%	$764.4M-10.1%	$850.1M
Inventory	N/A	N/A	N/A	N/A	N/A	N/A
Accounts Receivable	N/A	N/A	N/A	N/A	N/A	N/A
Goodwill	N/A	N/A	N/A	N/A	N/A	N/A
Total Liabilities	$39.8M+54.2%	$25.8M-35.1%	$39.8M+52.2%	$26.1M-58.4%	$62.8M-80.1%	$315.8M
Current Liabilities	$39.8M+113.9%	$18.6M-42.5%	$32.4M+75.2%	$18.5M-67.5%	$56.9M-82.0%	$315.8M
Long-Term Debt	N/A	N/A	N/A	N/A	N/A	N/A
Total Equity	$275.4M-37.2%	$438.9M-21.0%	$555.2M-13.3%	$640.6M-9.8%	$710.1M+29.6%	$547.8M
Retained Earnings	-$522.6M-43.5%	-$364.2M-86.0%	-$195.8M-227.1%	-$59.9M-206.9%	$56.0M+186.0%	-$65.2M

Metric	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24
Total Assets	$267.1M-15.3%	$315.2M-8.1%	$343.0M-12.4%	$391.6M-11.0%	$440.0M-5.3%	$464.7M-5.4%	$491.0M-3.8%	$510.4M
Current Assets	$263.2M-15.4%	$311.0M-7.5%	$336.1M-12.8%	$385.6M-11.1%	$433.7M-6.2%	$462.4M-5.0%	$486.9M-3.8%	$506.4M
Cash & Equivalents	$79.3M-17.1%	$95.7M+23.7%	$77.3M-11.8%	$87.7M-26.5%	$119.4M+84.5%	$64.7M-34.3%	$98.5M-59.5%	$243.4M
Inventory	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Accounts Receivable	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Goodwill	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Liabilities	$33.4M-16.1%	$39.8M+46.4%	$27.2M0.0%	$27.2M-5.9%	$28.9M+11.9%	$25.8M-20.5%	$32.4M-4.4%	$33.9M
Current Liabilities	$33.4M-16.1%	$39.8M+97.2%	$20.2M+0.3%	$20.1M-7.5%	$21.7M+16.9%	$18.6M-26.1%	$25.2M-5.4%	$26.6M
Long-Term Debt	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Equity	$233.7M-15.1%	$275.4M-12.8%	$315.8M-13.3%	$364.4M-11.4%	$411.1M-6.3%	$438.9M-4.3%	$458.5M-3.8%	$476.5M
Retained Earnings	-$568.0M-8.7%	-$522.6M-9.4%	-$477.7M-9.7%	-$435.7M-9.3%	-$398.5M-9.4%	-$364.2M-10.1%	-$330.7M-10.4%	-$299.5M

AVIR Cash Flow Statement

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Operating Cash Flow	-$132.0M+2.6%	-$135.5M-58.7%	-$85.4M+29.4%	-$121.0M-39.1%	-$87.0M-129.3%	$296.7M
Capital Expenditures	N/A	N/A	N/A	$1.9M+48475.0%	$4K-84.6%	$26K
Free Cash Flow	N/A	N/A	N/A	-$122.9M-41.3%	-$87.0M-129.3%	$296.7M
Investing Cash Flow	$188.8M+236.5%	$56.1M+39.2%	$40.3M+108.8%	-$455.4M-11385150.0%	-$4K+84.6%	-$26K
Financing Cash Flow	-$25.7M-9742.3%	$267K+3.9%	$257K-30.5%	$370K-74.7%	$1.5M-99.7%	$531.7M
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	$25.5M	$0	N/A	N/A	N/A	N/A

Metric	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24
Operating Cash Flow	-$46.4M-64.4%	-$28.2M+30.1%	-$40.4M-22.8%	-$32.9M-7.5%	-$30.6M-0.5%	-$30.4M-32.0%	-$23.0M+45.4%	-$42.2M
Capital Expenditures	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Free Cash Flow	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Investing Cash Flow	$29.7M-36.2%	$46.6M+12.8%	$41.3M+170.1%	$15.3M-82.1%	$85.6M+2640.3%	-$3.4M+97.2%	-$122.0M-197.9%	$124.7M
Financing Cash Flow	$257K	$0+100.0%	-$11.3M+19.8%	-$14.1M-3961.4%	-$347K	$0-100.0%	$117K	$0
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	$0-100.0%	$11.4M	N/A	N/A	N/A	N/A	N/A

AVIR Financial Ratios

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Gross Margin	N/A	N/A	N/A	N/A	N/A	N/A
Operating Margin	N/A	N/A	N/A	N/A	39.4%+62.1pp	-22.7%
Net Margin	N/A	N/A	N/A	N/A	34.4%+57.0pp	-22.5%
Return on Equity	-57.4%-19.1pp	-38.3%-13.8pp	-24.5%-6.4pp	-18.1%-35.2pp	17.0%+19.0pp	-2.0%
Return on Assets	-50.1%-14.0pp	-36.1%-13.3pp	-22.9%-5.5pp	-17.4%-33.1pp	15.7%+16.9pp	-1.3%
Current Ratio	7.82-17.0	24.85+6.6	18.24-17.5	35.77+22.2	13.58+10.8	2.73
Debt-to-Equity	0.14+0.1	0.06-0.0	0.07+0.0	0.04-0.0	0.09-0.5	0.58
FCF Margin	N/A	N/A	N/A	N/A	-24.8%-634.9pp	610.1%

Metric	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24
Gross Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Operating Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Net Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Return on Equity	-19.4%	N/A	-13.3%-3.1pp	-10.2%-1.9pp	-8.3%	N/A	-6.8%+1.7pp	-8.5%
Return on Assets	-17.0%	N/A	-12.3%-2.8pp	-9.5%-1.7pp	-7.8%	N/A	-6.3%+1.6pp	-7.9%
Current Ratio	7.89+0.1	7.82-8.8	16.66-2.5	19.17-0.8	19.94-4.9	24.85+5.5	19.33+0.3	19.02
Debt-to-Equity	0.140.0	0.14+0.1	0.09+0.0	0.070.0	0.07+0.0	0.06-0.0	0.070.0	0.07
FCF Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Similar Companies

Neumora Therapeutics Inc NMRA

$328.0M

Omeros OMER

$846.8M

Candel Therapeutics, Inc. CADL

$578.8M

Invivyd IVVD

$332.9M

Frequently Asked Questions

Is Atea Pharmaceuticals, Inc. profitable?

No, Atea Pharmaceuticals, Inc. (AVIR) reported a net income of -$158.0M in fiscal year 2025.

What is Atea Pharmaceuticals, Inc.'s EBITDA?

Atea Pharmaceuticals, Inc. (AVIR) had EBITDA of -$180.5M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.

What is Atea Pharmaceuticals, Inc.'s return on equity (ROE)?

Atea Pharmaceuticals, Inc. (AVIR) has a return on equity of -57.4% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.

What is Atea Pharmaceuticals, Inc.'s operating cash flow?

Atea Pharmaceuticals, Inc. (AVIR) generated -$132.0M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.

What are Atea Pharmaceuticals, Inc.'s total assets?

Atea Pharmaceuticals, Inc. (AVIR) had $315.2M in total assets as of fiscal year 2025, including both current and long-term assets.

How much does Atea Pharmaceuticals, Inc. spend on research and development?

Atea Pharmaceuticals, Inc. (AVIR) invested $148.0M in research and development during fiscal year 2025.

Does Atea Pharmaceuticals, Inc. buy back shares?

Yes, Atea Pharmaceuticals, Inc. (AVIR) spent $25.5M on share buybacks during fiscal year 2025, returning capital to shareholders by reducing shares outstanding.

How many shares does Atea Pharmaceuticals, Inc. have outstanding?

Atea Pharmaceuticals, Inc. (AVIR) had 78M shares outstanding as of fiscal year 2025.

What is Atea Pharmaceuticals, Inc.'s current ratio?

Atea Pharmaceuticals, Inc. (AVIR) had a current ratio of 7.82 as of fiscal year 2025, which is generally considered healthy.

What is Atea Pharmaceuticals, Inc.'s debt-to-equity ratio?

Atea Pharmaceuticals, Inc. (AVIR) had a debt-to-equity ratio of 0.14 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is Atea Pharmaceuticals, Inc.'s return on assets (ROA)?

Atea Pharmaceuticals, Inc. (AVIR) had a return on assets of -50.1% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

What is Atea Pharmaceuticals, Inc.'s cash runway?

Based on fiscal year 2025 data, Atea Pharmaceuticals, Inc. (AVIR) had $95.7M in cash against an annual operating cash burn of $132.0M. This gives an estimated cash runway of approximately 9 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.

What is Atea Pharmaceuticals, Inc.'s Piotroski F-Score?

Atea Pharmaceuticals, Inc. (AVIR) has a Piotroski F-Score of 2 out of 9, indicating weak financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are Atea Pharmaceuticals, Inc.'s earnings high quality?

Atea Pharmaceuticals, Inc. (AVIR) has an earnings quality ratio of 0.84x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

How financially healthy is Atea Pharmaceuticals, Inc.?

Atea Pharmaceuticals, Inc. (AVIR) scores 33 out of 100 on our Financial Profile, indicating weak overall financial health. This composite score evaluates six dimensions: profitability (operating margin), revenue growth, leverage (debt-to-equity), liquidity (current ratio), cash flow quality (free cash flow margin), and shareholder returns (return on equity). Each dimension is normalized against standard financial benchmarks. Learn more in our complete guide to financial health indicators.